icon-folder.gif   Conference Reports for NATAP  
  EASL - The International Liver Congress 2015
50th Annual Meeting of the European
Association for the Study of the Liver
Vienna, Austria  April 22-26
Back grey_arrow_rt.gif
A Randomized, Open-Label Study to Evaluate Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I)
  Reported by Jules Levin
European Association for the Study of the Liver, 50th International Liver
Congress 2015, 22-26 April 2015, Vienna, Austria
Tarik Asselah1, Tarek Hassanein2, Roula B Qaqish3, Jordan J Feld4, Christophe Hezode5, Stefan Zeuzem6, Peter Ferenci7, Tami Pilot-Matias3, Yao Yu3, Niloufar Mobashery3
1Centre de Recherche sur l'Inflammation, Inserm UMR 1149, Université Paris Diderot, AP-HP Hôpital Beaujon, Clichy, France; 2Southern California Liver Centers and Southern California Research Center, Coronado, California, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Toronto Centre for Liver Disease, University of Toronto, Toronto, Canada; 5Henri Mondor University Hospital, AP-HP, Université Paris-Est, Créteil, France; 6J.W. Goethe University, Frankfurt, Germany; 7Medical University Vienna, Vienna, Austria